Feature

Diabetes drugs with cardiovascular benefits broaden cardiology’s turf

Publish date: November 9, 2016

 

On Twitter @mitchelzoler

Pages

Recommended Reading

FDA cancels REMS for rosiglitazone
MDedge Endocrinology
Primary care endures in heart failure management
MDedge Endocrinology
AHA: Bariatric surgery slashes heart failure exacerbations
MDedge Endocrinology
Two new drugs
MDedge Endocrinology
No LIGHT shed on CV safety of naltrexone-bupropion
MDedge Endocrinology
Incretin-based diabetes drugs don’t raise heart failure risk
MDedge Endocrinology
FDA adds safety warnings to certain type 2 diabetes medications
MDedge Endocrinology
No rise in serious HF seen in patients taking saxagliptin or sitagliptin
MDedge Endocrinology
Statement warns of drugs causing or exacerbating heart failure
MDedge Endocrinology
Palliative care boosts heart failure patient outcomes
MDedge Endocrinology